Two Arcadia Biosciences (NASDAQ: RKDA) directors step down

Rhea-AI Filing Summary

Arcadia Biosciences, Inc. reported that two members of its board of directors, Albert D. Bolles, Ph.D. and Deborah Carosella, resigned from the board effective February 4, 2026.

Bolles served on the Compensation Committee, while Carosella served on both the Compensation Committee and the Nominating and Governance Committee. The company stated that their resignations were not due to any disagreement with the company or its board regarding operations, policies, practices, or financial statements. Both former directors agreed to remain available to assist the company in an advisory capacity.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000146944300014694432026-02-042026-02-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 04, 2026

Arcadia Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37383	81-0571538
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
5956 Sherry Lane Suite 2000
Dallas, Texas				75225
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 214 974-8921

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common		RKDA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Resignation of Directors

On February 4, 2026, each of Albert D. Bolles, Ph.D., a director and member of the Compensation Committee of the board of directors (the "Board") of Arcadia Biosciences, Inc. (the "Company"), and Deborah Carosella, a director and member of the Compensation Committee and Nominating and Governance Committee of the Board, notified the Company that effective as of February 4, 2026, such person was resigning as a director of the Company and all subsidiaries of the Company of which such person was a director. Their resignation was not because of any disagreement with the Company or the Board on any matter relating to the Company’s operations, policies, practices or financial statements. Each person agreed to be available to provide assistance as an advisor.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

None.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ARCADIA BIOSCIENCES, INC.
Date:	February 6, 2026	By:	/s/ THOMAS J. SCHAEFER
			Thomas J. Schaefer, Chief Executive Officer

FAQ

What board changes did Arcadia Biosciences (RKDA) disclose in this 8-K?

Arcadia Biosciences disclosed that directors Albert D. Bolles, Ph.D. and Deborah Carosella resigned from its board effective February 4, 2026. Both also stepped down from their board committee roles but agreed to be available to assist the company as advisors.

When did the Arcadia Biosciences directors’ resignations become effective?

The resignations of Albert D. Bolles, Ph.D. and Deborah Carosella became effective on February 4, 2026. On that date, each left the Arcadia Biosciences board and all subsidiary boards where they served as directors.

Did the Arcadia Biosciences directors resign due to disagreements with the company?

No. The company stated that the resignations of Albert D. Bolles, Ph.D. and Deborah Carosella were not because of any disagreement with Arcadia Biosciences or its board on operations, policies, practices, or financial statements, indicating no reported dispute behind the decision.

What committee roles did the resigning Arcadia Biosciences directors hold?

Albert D. Bolles, Ph.D. served as a member of the Compensation Committee. Deborah Carosella served on both the Compensation Committee and the Nominating and Governance Committee of the Arcadia Biosciences board before their resignations.

Will the resigning Arcadia Biosciences directors remain involved with the company?

Yes. Although Albert D. Bolles, Ph.D. and Deborah Carosella resigned from the board and subsidiaries, each agreed to be available to provide assistance to Arcadia Biosciences as an advisor, allowing the company to draw on their experience if needed.

Who signed the Arcadia Biosciences 8-K reporting these director resignations?

The 8-K was signed on behalf of Arcadia Biosciences by Thomas J. Schaefer, the company’s Chief Executive Officer, dated February 6, 2026, confirming the board changes and related disclosures in the current report.